Navigation Links
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
Date:3/18/2009

offset our early stage expenses. As a result, we have ended the quarter at $3.6 million in cash and Certificates of Deposit vs. $3.7 million at April 30, 2008. Our revenue generation reduces our risk and provides a significant part of the capital required to grow high potential initiatives. We believe that this strategy gives us an advantage in this economic climate, while many in the biotech industry are more adversely affected by the financial crisis," stated Douglas Burkett, Ph.D., President of Champions Biotechnology, Inc. "Although our third quarter revenues of $1,052,175 were just slightly higher than our second quarter revenue of $1,044,172, the Company's deferred revenue in the third quarter climbed to $1,361,110 compared to $461,838 for our second quarter ended October 31, 2008.

"We intend to grow revenue from our Personalized Oncology and Preclinical eValuation businesses as we build our own drug pipeline," continued Dr. Burkett. "During the third quarter we identified oncology drug candidates from academic centers, pharmaceutical and biotech companies and began negotiations with license holders. We intend to leverage our predictive platform to screen drug candidates and acquire, or partner to develop, drug candidates that demonstrate efficacy in our Biomerk Tumorgraft models. The Company plans to partner with pharmaceutical or biotechnology companies to advance its drugs through remaining preclinical and clinical trials."

Highlights of the Company's third quarter ending January 31, 2009:

  1. The Company continued to expand its preclinical eValuation platform through additional collaborations to acquire tumor samples and by implanting, propagating and storing banks of Biomerk Tumorgrafts(TM) for use in future analysis of oncology drugs.
  2. The growing platform of Biomerk Tumorgrafts generated growing interest from large and small pharmaceutical and biotechnology compan
    '/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
2. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
4. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
8. Canadian Government Announces Funding for Leading Biotechnology Firms Project
9. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
10. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Bioptigen announced today the availability ... the optical device metrology and pre-clinical ophthalmic research markets. ... for Contact Lens Metrology is designed for non-destructive, non-contact, ... lens, IOL structures, and donor tissues. The ... immersed in a hydration bath (saline), automated segmentation of ...
(Date:9/15/2014)... Research and Markets has announced the ... by Services, by Technology, by Application - Global Forecast to ... Exome Sequencing (WES) is next-generation technology used for strategically sequencing ... exome, which is the total of all exons of an ... actually converted into proteins after translation. It is responsible for ...
(Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
(Date:9/15/2014)... , Sept. 15, 2014  The second annual ... celebrated October 12-18. A joint initiative of the ... member companies , IPAW is designed to: ... , Recognize the contributions of plasma donors in saving ... plasma protein therapies and rare diseases ...
Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... 6 CryoLife, Inc., (NYSE: ... processing company, today announced that it has received a Humanitarian ... (FDA) for its CryoValve® SG aortic human heart valve. ... Humanitarian Device Exemption (HDE) for the CryoValve SG aortic human ...
... , PALO ALTO, Calif., Oct. 6 Varian, Inc. (NasdaqGS: VARI) ... October 5, 2009, its stockholders adopted the merger agreement entered ... Varian for $52.00 per share in cash. Approximately 84% ... August 12, 2009, the record date for the special meeting, ...
... ... today announced its sole focus of delivering novel nanotechnology solutions for instantly assessing ... world, without requiring a costly, complex medical infrastructure. , ... Santa Barbara, CA (PRWEB) October ...
Cached Biology Technology:CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 2Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 3Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 4
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
(Date:9/15/2014)... When this week,s print issue of the journal ... up from New Mexico, Montana and even the Netherlands, ... more and more the norm in these connected times. ... it will produce innovations in biology, medicine, biotechnology and ... this scientist talked with that one, that one knew ...
(Date:9/15/2014)... A new strategic vision document, released today by ... describes the long-term goals, objectives, and strategies for ... work over the next five years (2015-2020). ... short-term activities, to be funded in 2015, will ... policy fellowships. , The $500 million, 30-year ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Collaboration drives achievement in protein structure research 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... researchers have proved that eating strawberries reduces the harm ... Published in the open access journal Plos One, the ... ulcers. A team of Italian, Serbian and Spanish ... in a mammal stomach that has been damaged by ...
... of a brain protein that regulates gene expression may play ... and sometimes disabling psychiatric disease. As reported in the latest ... International Society for Bipolar Disorders, levels of SP4 (specificity protein ... in postmortem samples from patients with bipolar disorder. The study ...
... latest issue of Elsevier,s Materials Today , researchers ... of carbon nanotubes to create mechanical components for use ... industry has excelled in miniaturizing components, with individual elements ... reducing the size of mechanical systems has proved much ...
Cached Biology News:Strawberries protect the stomach from alcohol 2Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3Nanotubes key to microscopic mechanics 2
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... 2000 One-Step FP Standardization Kit is ... low fluorescence polarization values of fluorescein ... Beacon 2000 System. It also allows ... generated by their instrument to the ...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Biology Products: